Browse > Article
http://dx.doi.org/10.5483/BMBRep.2022.55.7.073

Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson's disease  

Yoo, Hajung (Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University)
Lee, Jeongmin (Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University)
Kim, Bokwang (Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University)
Moon, Heechang (Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University)
Jeong, Huisu (Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University)
Lee, Kyungmi (Department of Medicine, College of Medicine, Hanyang University)
Song, Woo Jeung (Department of Medical Genetics, College of Medicine, Hanyang University)
Hur, Junho K. (Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University)
Oh, Yohan (Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University)
Publication Information
BMB Reports / v.55, no.7, 2022 , pp. 323-335 More about this Journal
Abstract
Together with neuronal loss, the existence of insoluble inclusions of alpha-synuclein (α-syn) in the brain is widely accepted as a hallmark of synucleinopathies including Parkinson's disease (PD), multiple system atrophy, and dementia with Lewy body. Because the α-syn aggregates are deeply involved in the pathogenesis, there have been many attempts to demonstrate the mechanism of the aggregation and its potential causative factors including post-translational modifications (PTMs). Although no concrete conclusions have been made based on the previous study results, growing evidence suggests that modifications such as phosphorylation and ubiquitination can alter α-syn characteristics to have certain effects on the aggregation process in PD; either facilitating or inhibiting fibrillization. In the present work, we reviewed studies showing the significant impacts of PTMs on α-syn aggregation. Furthermore, the PTMs modulating α-syn aggregation-induced cell death have been discussed.
Keywords
Alpha-synuclein; Parkinson's disease; Post-translational modification; Protein aggregation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Bartels T, Kim NC, Luth ES and Selkoe DJ (2014) Nalpha-acetylation of alpha-synuclein increases its helical folding propensity, GM1 binding specificity and resistance to aggregation. PLoS One 9, e103727   DOI
2 Watson MD and Lee JC (2019) N-terminal acetylation affects alpha-synuclein fibril polymorphism. Biochemistry 58, 3630-3633   DOI
3 Dikiy I and Eliezer D (2014) N-terminal acetylation stabilizes N-terminal helicity in lipid- and micelle-bound alpha-synuclein and increases its affinity for physiological membranes. J Biol Chem 289, 3652-3665   DOI
4 Lorentzon E, Kumar R, Horvath I and Wittung-Stafshede P (2020) Differential effects of Cu(2+) and Fe(3+) ions on in vitro amyloid formation of biologically-relevant alpha-synuclein variants. Biometals 33, 97-106   DOI
5 Hejjaoui M, Haj-Yahya M, Kumar KS, Brik A and Lashuel HA (2011) Towards elucidation of the role of ubiquitination in the pathogenesis of Parkinson's disease with semisynthetic ubiquitinated alpha-synuclein. Angew Chem Int Ed Engl 50, 405-409   DOI
6 Gerez JA, Prymaczok NC, Rockenstein E et al (2019) A cullin-RING ubiquitin ligase targets exogenous alpha-synuclein and inhibits Lewy body-like pathology. Sci Transl Med 11, eaau6722   DOI
7 Ye Y, Klenerman D and Finley D (2020) N-terminal ubiquitination of amyloidogenic proteins triggers removal of their oligomers by the proteasome holoenzyme. J Mol Biol 432, 585-596   DOI
8 Moon SP, Balana AT, Galesic A, Rakshit A and Pratt MR (2020) Ubiquitination can change the structure of the alpha-synuclein amyloid fiber in a site selective fashion. J Org Chem 85, 1548-1555   DOI
9 Rott R, Szargel R, Shani V et al (2017) SUMOylation and ubiquitination reciprocally regulate alpha-synuclein degradation and pathological aggregation. Proc Natl Acad Sci U S A 114, 13176-13181   DOI
10 Wang S, Yang F, Petyuk VA et al (2017) Quantitative proteomics identifies altered O-GlcNAcylation of structural, synaptic and memory-associated proteins in Alzheimer's disease. J Pathol 243, 78-88   DOI
11 Luk KC, Song C, O'Brien P et al (2009) Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A 106, 20051-20056   DOI
12 Pountney DL, Huang Y, Burns RJ et al (2003) SUMO-1 marks the nuclear inclusions in familial neuronal intra-nuclear inclusion disease. Exp Neurol 184, 436-446   DOI
13 Kim YM, Jang WH, Quezado MM et al (2011) Proteasome inhibition induces alpha-synuclein SUMOylation and aggregate formation. J Neurol Sci 307, 157-161   DOI
14 Abeywardana T and Pratt MR (2015) Extent of inhibition of alpha-synuclein aggregation in vitro by SUMOylation is conjugation site- and SUMO isoform-selective. Biochemistry 54, 959-961   DOI
15 Haj-Yahya M, Fauvet B, Herman-Bachinsky Y et al (2013) Synthetic polyubiquitinated alpha-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology. Proc Natl Acad Sci U S A 110, 17726-17731   DOI
16 Krumova P, Meulmeester E, Garrido M et al (2011) Sumoylation inhibits alpha-synuclein aggregation and toxicity. J Cell Biol 194, 49-60   DOI
17 Baba M, Nakajo S, Tu PH et al (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152, 879-884
18 Muntane G, Ferrer I and Martinez-Vicente M (2012) alpha-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience 200, 106-119   DOI
19 Iyer A, Roeters SJ, Kogan V, Woutersen S, Claessens M and Subramaniam V (2017) C-terminal truncated alpha-synuclein fibrils contain strongly twisted beta-sheets. J Am Chem Soc 139, 15392-15400   DOI
20 Hoyer W, Cherny D, Subramaniam V and Jovin TM (2004) Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry 43, 16233-16242   DOI
21 Klein C and Westenberger A (2012) Genetics of Parkinson's disease. Cold Spring Harb Perspect Med 2, a008888   DOI
22 Giasson BI, Duda JE, Murray IV et al (2000) Oxidative damage linked to neurodegeneration by selective alphasynuclein nitration in synucleinopathy lesions. Science 290, 985-989   DOI
23 Waxman EA and Giasson BI (2008) Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J Neuropathol Exp Neurol 67, 402-416   DOI
24 Munch G, Luth HJ, Wong A et al (2000) Crosslinking of alpha-synuclein by advanced glycation endproducts--an early pathophysiological step in Lewy body formation? J Chem Neuroanat 20, 253-257   DOI
25 Li W, West N, Colla E et al (2005) Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A 102, 2162-2167   DOI
26 Maltsev AS, Ying J and Bax A (2012) Impact of N-terminal acetylation of alpha-synuclein on its random coil and lipid binding properties. Biochemistry 51, 5004-5013   DOI
27 Lima VA, do Nascimento LA, Eliezer D and Follmer C (2019) Role of Parkinson's disease-linked mutations and N-terminal acetylation on the oligomerization of alpha-synuclein Induced by 3,4-dihydroxyphenylacetaldehyde. ACS Chem Neurosci 10, 690-703   DOI
28 Mishizen-Eberz AJ, Norris EH, Giasson BI et al (2005) Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry 44, 7818-7829   DOI
29 Mishizen-Eberz AJ, Guttmann RP, Giasson BI et al (2003) Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J Neurochem 86, 836-847   DOI
30 Kasai T, Tokuda T, Yamaguchi N et al (2008) Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro. Neurosci Lett 436, 52-56   DOI
31 Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047   DOI
32 Emamzadeh FN (2016) Alpha-synuclein structure, functions, and interactions. J Res Med Sci 21, 29   DOI
33 McCann H, Stevens CH, Cartwright H and Halliday GM (2014) alpha-Synucleinopathy phenotypes. Parkinsonism Relat Disord 20 Suppl 1, S62-S67   DOI
34 Li JY, Englund E, Holton JL et al (2008) Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14, 501-503   DOI
35 Terada M, Suzuki G, Nonaka T, Kametani F, Tamaoka A and Hasegawa M (2018) The effect of truncation on prion-like properties of alpha-synuclein. J Biol Chem 293, 13910-13920   DOI
36 Brahmachari S, Ge P, Lee SH et al (2016) Activation of tyrosine kinase c-Abl contributes to alpha-synuclein-induced neurodegeneration. J Clin Invest 126, 2970-2988   DOI
37 Dufty BM, Warner LR, Hou ST et al (2007) Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am J Pathol 170, 1725-1738   DOI
38 Bartels T, Choi JG and Selkoe DJ (2011) alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107-110   DOI
39 Fusco G, Chen SW, Williamson PTF et al (2017) Structural basis of membrane disruption and cellular toxicity by alpha-synuclein oligomers. Science 358, 1440-1443   DOI
40 Yasuda T, Nakata Y and Mochizuki H (2013) alpha-Synuclein and neuronal cell death. Mol Neurobiol 47, 466-483   DOI
41 Benskey MJ, Perez RG and Manfredsson FP (2016) The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease. J Neurochem 137, 331-359   DOI
42 Sherer TB, Betarbet R, Stout AK et al (2002) An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 22, 7006-7015   DOI
43 Scudamore O and Ciossek T (2018) Increased oxidative stress exacerbates alpha-synuclein aggregation in vivo. J Neuropathol Exp Neurol 77, 443-453   DOI
44 Musgrove RE, Helwig M, Bae EJ et al (2019) Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular alpha-synuclein transfer. J Clin Invest 129, 3738-3753   DOI
45 Xilouri M, Brekk OR and Stefanis L (2013) alpha-Synuclein and protein degradation systems: a reciprocal relationship. Mol Neurobiol 47, 537-551   DOI
46 Tuttle MD, Comellas G, Nieuwkoop AJ et al (2016) Solid-state NMR structure of a pathogenic fibril of full-length human alpha-synuclein. Nat Struct Mol Biol 23, 409-415   DOI
47 Ni X, McGlinchey RP, Jiang J and Lee JC (2019) Structural insights into alpha-synuclein fibril polymorphism: Effects of Parkinson's disease-related C-terminal truncations. J Mol Biol 431, 3913-3919   DOI
48 Anderson JP, Walker DE, Goldstein JM et al (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281, 29739-29752   DOI
49 Machiya Y, Hara S, Arawaka S et al (2010) Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. J Biol Chem 285, 40732-40744   DOI
50 Alfaro JF, Gong CX, Monroe ME et al (2012) Tandem mass spectrometry identifies many mouse brain O-GlcNA-cylated proteins including EGF domain-specific O-GlcNAc transferase targets. Proc Natl Acad Sci U S A 109, 7280-7285   DOI
51 Yamin G, Uversky VN and Fink AL (2003) Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett 542, 147-152   DOI
52 Seo J and Lee KJ (2004) Post-translational modifications and their biological functions: proteomic analysis and systematic approaches. J Biochem Mol Biol 37, 35-44
53 Kang L, Moriarty GM, Woods LA, Ashcroft AE, Radford SE and Baum J (2012) N-terminal acetylation of alpha-synuclein induces increased transient helical propensity and decreased aggregation rates in the intrinsically disordered monomer. Protein Sci 21, 911-917   DOI
54 Sevcsik E, Trexler AJ, Dunn JM and Rhoades E (2011) Allostery in a disordered protein: oxidative modifications to alpha-synuclein act distally to regulate membrane binding. J Am Chem Soc 133, 7152-7158   DOI
55 Pronin AN, Morris AJ, Surguchov A and Benovic JL (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J Biol Chem 275, 26515-26522   DOI
56 Mbefo MK, Paleologou KE, Boucharaba A et al (2010) Phosphorylation of synucleins by members of the Pololike kinase family. J Biol Chem 285, 2807-2822   DOI
57 Li Y, Zhao C, Luo F et al (2018) Amyloid fibril structure of alpha-synuclein determined by cryo-electron microscopy. Cell Res 28, 897-903   DOI
58 Morris M, Knudsen GM, Maeda S et al (2015) Tau posttranslational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat Neurosci 18, 1183-1189   DOI
59 Marotta NP, Lin YH, Lewis YE et al (2015) O-GlcNAc modification blocks the aggregation and toxicity of the protein alpha-synuclein associated with Parkinson's disease. Nat Chem 7, 913-920   DOI
60 Sato H, Arawaka S, Hara S et al (2011) Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J Neurosci 31, 16884-16894   DOI
61 Burai R, Ait-Bouziad N, Chiki A and Lashuel HA (2015) Elucidating the role of site-specific nitration of alpha-synuclein in the pathogenesis of Parkinson's disease via protein semisynthesis and mutagenesis. J Am Chem Soc 137, 5041-5052   DOI
62 Lewis YE, Galesic A, Levine PM et al (2017) O-GlcNAcylation of alpha-synuclein at serine 87 reduces aggregation without affecting membrane binding. ACS Chem Biol 12, 1020-1027   DOI
63 Sharma N, Rao SP and Kalivendi SV (2019) The deglycase activity of DJ-1 mitigates alpha-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease. Free Radic Biol Med 135, 28-37   DOI
64 Hodara R, Norris EH, Giasson BI et al (2004) Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J Biol Chem 279, 47746-47753   DOI
65 Chen SW, Drakulic S, Deas E et al (2015) Structural characterization of toxic oligomers that are kinetically trapped during alpha-synuclein fibril formation. Proc Natl Acad Sci U S A 112, E1994-E2003
66 Chen L, Wei Y, Wang X and He R (2010) Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products. PLoS One 5, e9052   DOI
67 Marino L, Ramis R, Casasnovas R et al (2020) Unravelling the effect of N(epsilon)-(carboxyethyl)lysine on the conformation, dynamics and aggregation propensity of alpha-synuclein. Chem Sci 11, 3332-3344   DOI
68 Lee D, Park CW, Paik SR and Choi KY (2009) The modification of alpha-synuclein by dicarbonyl compounds inhibits its fibril-forming process. Biochim Biophys Acta 1794, 421-430   DOI
69 Norris EH, Giasson BI, Ischiropoulos H and Lee VM (2003) Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J Biol Chem 278, 27230-27240   DOI
70 Qiao HH, Zhu LN, Wang Y et al (2019) Implications of alpha-synuclein nitration at tyrosine 39 in methamphetamine-induced neurotoxicity in vitro and in vivo. Neural Regen Res 14, 319-327   DOI
71 Fujiwara H, Hasegawa M, Dohmae N et al (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4, 160-164   DOI
72 Vicente Miranda H, Szego EM, Oliveira LMA et al (2017) Glycation potentiates alpha-synuclein-associated neurodegeneration in synucleinopathies. Brain 140, 1399-1419   DOI
73 van der Wateren IM, Knowles TPJ, Buell AK, Dobson CM and Galvagnion C (2018) C-terminal truncation of alpha-synuclein promotes amyloid fibril amplification at physiological pH. Chem Sci 9, 5506-5516   DOI
74 Negro A, Brunati AM, Donella-Deana A, Massimino ML and Pinna LA (2002) Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosininduced aggregation. FASEB J 16, 210-212
75 Shin WH and Chung KC (2020) Death-associated protein kinase 1 phosphorylates alpha-synuclein at Ser129 and exacerbates rotenone-induced toxic aggregation of alpha-synuclein in dopaminergic SH-SY5Y cells. Exp Neurobiol 29, 207-218   DOI
76 Nakamura T, Yamashita H, Takahashi T and Nakamura S (2001) Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. Biochem Biophys Res Commun 280, 1085-1092   DOI
77 Ellis CE, Schwartzberg PL, Grider TL, Fink DW and Nussbaum RL (2001) alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases. J Biol Chem 276, 3879-3884   DOI
78 Sorrentino ZA, Hass E, Vijayaraghavan N et al (2020) Carboxy-terminal truncation and phosphorylation of alpha-synuclein elongates survival in a prion-like seeding mouse model of synucleinopathy. Neurosci Lett 732, 135017   DOI
79 Stefanis L, Emmanouilidou E, Pantazopoulou M, Kirik D, Vekrellis K and Tofaris GK (2019) How is alpha-synuclein cleared from the cell? J Neurochem 150, 577-590   DOI
80 Shin Y, Klucken J, Patterson C, Hyman BT and McLean PJ (2005) The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem 280, 23727-23734   DOI
81 Tetzlaff JE, Putcha P, Outeiro TF et al (2008) CHIP targets toxic alpha-Synuclein oligomers for degradation. J Biol Chem 283, 17962-17968   DOI
82 Nishie M, Mori F, Yoshimoto M, Takahashi H and Wakabayashi K (2004) A quantitative investigation of neuronal cytoplasmic and intranuclear inclusions in the pontine and inferior olivary nuclei in multiple system atrophy. Neuropathol Appl Neurobiol 30, 546-554   DOI
83 Waxman EA and Giasson BI (2011) Characterization of kinases involved in the phosphorylation of aggregated alpha-synuclein. J Neurosci Res 89, 231-247   DOI
84 Spillantini MG, Crowther RA, Jakes R, Hasegawa M and Goedert M (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 95, 6469-6473   DOI
85 Trojanowski JQ, Revesz T and Neuropathology Working Group on MSA (2007) Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 33, 615-620   DOI
86 Fauvet B, Mbefo MK, Fares MB et al (2012) alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem 287, 15345-15364   DOI
87 Cremades N, Cohen SI, Deas E et al (2012) Direct observation of the interconversion of normal and toxic forms of alpha-synuclein. Cell 149, 1048-1059   DOI
88 Mahul-Mellier AL, Burtscher J, Maharjan N et al (2020) The process of Lewy body formation, rather than simply alpha-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc Natl Acad Sci U S A 117, 4971-4982   DOI
89 Chen L and Feany MB (2005) Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8, 657-663   DOI
90 Chen L, Periquet M, Wang X et al (2009) Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest 119, 3257-3265   DOI
91 Okochi M, Walter J, Koyama A et al (2000) Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J Biol Chem 275, 390-397   DOI
92 Paleologou KE, Oueslati A, Shakked G et al (2010) Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci 30, 3184-3198   DOI
93 Smith WW, Margolis RL, Li X et al (2005) Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J Neurosci 25, 5544-5552   DOI
94 Ding J, Wang Y, Huang J et al (2020) Role of alpha-synuclein phosphorylation at Serine 129 in methamphetamine-induced neurotoxicity in vitro and in vivo. Neuroreport 31, 787-797
95 Oueslati A, Schneider BL, Aebischer P and Lashuel HA (2013) Polo-like kinase 2 regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vivo. Proc Natl Acad Sci U S A 110, E3945-E3954
96 Rott R, Szargel R, Haskin J et al (2008) Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J Biol Chem 283, 3316-3328   DOI
97 Lee JT, Wheeler TC, Li L and Chin LS (2008) Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death. Hum Mol Genet 17, 906-917   DOI
98 Oh Y, Kim YM, Mouradian MM and Chung KC (2011) Human Polycomb protein 2 promotes alpha-synuclein aggregate formation through covalent SUMOylation. Brain Res 1381, 78-89   DOI
99 Prasad V, Wasser Y, Hans F et al (2019) Monitoring alpha-synuclein multimerization in vivo. FASEB J 33, 2116-2131   DOI
100 Lashuel HA, Petre BM, Wall J et al (2002) Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322, 1089-1102   DOI
101 Oueslati A, Paleologou KE, Schneider BL, Aebischer P and Lashuel HA (2012) Mimicking phosphorylation at serine 87 inhibits the aggregation of human alpha-synuclein and protects against its toxicity in a rat model of Parkinson's disease. J Neurosci 32, 1536-1544   DOI
102 Tofaris GK, Kim HT, Hourez R, Jung JW, Kim KP and Goldberg AL (2011) Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway. Proc Natl Acad Sci U S A 108, 17004-17009   DOI
103 Levine PM, Galesic A, Balana AT et al (2019) alpha-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease. Proc Natl Acad Sci U S A 116, 1511-1519   DOI
104 Davies SE, Hallett PJ, Moens T et al (2014) Enhanced ubiquitin-dependent degradation by Nedd4 protects against alpha-synuclein accumulation and toxicity in animal models of Parkinson's disease. Neurobiol Dis 64, 79-87   DOI
105 Danzer KM, Haasen D, Karow AR et al (2007) Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 27, 9220-9232   DOI
106 Peelaerts W, Bousset L, Van der Perren A et al (2015) alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522, 340-344   DOI
107 Volpicelli-Daley LA, Luk KC, Patel TP et al (2011) Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57-71   DOI
108 Zhang J, Lei H, Chen Y et al (2017) Enzymatic O-GlcNA-cylation of alpha-synuclein reduces aggregation and increases SDS-resistant soluble oligomers. Neurosci Lett 655, 90-94   DOI
109 Vijayakumaran S, Nakamura Y, Henley JM and Pountney DL (2019) Ginkgolic acid promotes autophagy-dependent clearance of intracellular alpha-synuclein aggregates. Mol Cell Neurosci 101, 103416   DOI
110 Shahpasandzadeh H, Popova B, Kleinknecht A, Fraser PE, Outeiro TF and Braus GH (2014) Interplay between sumoylation and phosphorylation for protection against alpha-synuclein inclusions. J Biol Chem 289, 31224-31240   DOI
111 Campbell BC, McLean CA, Culvenor JG et al (2001) The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J Neurochem 76, 87-96   DOI
112 Murray IV, Giasson BI, Quinn SM et al (2003) Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42, 8530-8540   DOI
113 Serpell LC, Berriman J, Jakes R, Goedert M and Crowther RA (2000) Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A 97, 4897-4902   DOI
114 Periquet M, Fulga T, Myllykangas L, Schlossmacher MG and Feany MB (2007) Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 27, 3338-3346   DOI
115 Zhang Z, Kang SS, Liu X et al (2017) Asparagine endopeptidase cleaves alpha-synuclein and mediates pathologic activities in Parkinson's disease. Nat Struct Mol Biol 24, 632-642   DOI
116 McGlinchey RP, Lacy SM, Huffer KE, Tayebi N, Sidransky E and Lee JC (2019) C-terminal alpha-synuclein truncations are linked to cysteine cathepsin activity in Parkinson's disease. J Biol Chem 294, 9973-9984   DOI
117 Tofaris GK, Garcia Reitbock P, Humby T et al (2006) Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J Neurosci 26, 3942-3950   DOI
118 Marotta NP, Cherwien CA, Abeywardana T and Pratt MR (2012) O-GlcNAc modification prevents peptide-dependent acceleration of alpha-synuclein aggregation. ChemBioChem 13, 2665-2670   DOI
119 Ryan P, Xu M, Davey AK et al (2019) O-GlcNAc modification protects against protein misfolding and aggregation in neurodegenerative disease. ACS Chem Neurosci 10, 2209-2221   DOI
120 Braak H, Ghebremedhin E, Rub U, Bratzke H and Del Tredici K (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318, 121-134   DOI
121 Nakajo S, Tsukada K, Omata K, Nakamura Y and Nakaya K (1993) A new brain-specific 14-kDa protein is a phosphoprotein. Its complete amino acid sequence and evidence for phosphorylation. Eur J Biochem 217, 1057-1063   DOI
122 Moons R, Konijnenberg A, Mensch C et al (2020) Metal ions shape alpha-synuclein. Sci Rep 10, 16293   DOI
123 Burmann BM, Gerez JA, Matecko-Burmann I et al (2020) Regulation of alpha-synuclein by chaperones in mammalian cells. Nature 577, 127-132   DOI
124 Meier F, Abeywardana T, Dhall A et al (2012) Semisynthetic, site-specific ubiquitin modification of alpha-synuclein reveals differential effects on aggregation. J Am Chem Soc 134, 5468-5471   DOI